Tumor Treatment

Abstract

A method for treating a tumor in a host in vivo, where the tumor has a centralized necrotic region, an intermediate hypoxic region, and a peripheral vascularized region. An antidotal agent is administered to the host intravenously, and a period of time is allowed for the antidotal agent to perfuse into vascularized cells in the host. A cell-killing agent is administered directly into the centralized region of the tumor, whereby hydrostatic pressure within the tumor forces the cell-killing agent out of the centralized region of the tumor and through the intermediate region of the tumor in an interstitial flow, killing any non-vascularized cells in the centralized region and the intermediate region. The cell-killing agent is neutralized by the antidotal agent as the cell-killing agent passes through the vascularized cells in the peripheral region.

1 . A method for treating a tumor in a host in vivo, where the tumor has a centralized necrotic region, an intermediate hypoxic region, and a peripheral vascularized region, the method comprising the steps of:
 administering an antidotal agent to the host intravenously,   waiting for a period of time for the antidotal agent to perfuse into vascularized cells in the host, and   administering a cell-killing agent directly into the centralized region of the tumor,   whereby hydrostatic pressure within the tumor forces the cell-killing agent out of the centralized region of the tumor and through the intermediate region of the tumor in an interstitial flow, killing any non-vascularized cells in the centralized region and the intermediate region, and   whereby the cell-killing agent is neutralized by the antidotal agent as the cell-killing agent passes through the vascularized cells in the peripheral region.   
     
     
         2 . The method of  claim 1 , wherein the antidotal agent comprises silver. 
     
     
         3 . The method of  claim 2 , further comprising, prior to the step of administering the antidotal agent:
 administering methylene blue to the tumor, and   administering a super-physiological dose of vitamin C to the tumor, thereby producing leucomethylene blue and dehydroascorbic acid within the tumor.   
     
     
         4 . The method of  claim 3 , further comprising administering at least one of grape seed proanthocyanidins and a lipid-soluble antioxidant. 
     
     
         5 . The method of  claim 1 , wherein the cell-killing agent comprises an injectable selenite-containing hydrogel. 
     
     
         6 . The method of  claim 1 , wherein the cell-killing agent comprises an H2S donor, including at least one of sodium hydrosulfide, sodium sulfide, and GYY4137. 
     
     
         7 . A method for treating a tumor in a host in vivo, where the tumor has a centralized necrotic region, an intermediate hypoxic region, and a peripheral vascularized region, the method comprising the steps of:
 administering methylene blue to the tumor,   administering a super-physiological dose of vitamin C to the tumor, thereby producing leucomethylene blue and dehydroascorbic acid within the tumor,   administering a silver-containing antidotal agent to the host intravenously,   waiting for a period of time for the antidotal agent to perfuse into vascularized cells in the host, and   administering a cell-killing agent directly into the centralized region of the tumor,   whereby hydrostatic pressure within the tumor forces the cell-killing agent out of the centralized region of the tumor and through the intermediate region of the tumor in an interstitial flow, killing any non-vascularized cells in the centralized region and the intermediate region, and   whereby the cell-killing agent is neutralized by the antidotal agent as the cell-killing agent passes through the vascularized cells in the peripheral region.   
     
     
         8 . The method of  claim 7 , further comprising administering at least one of grape seed proanthocyanidins and a lipid-soluble antioxidant. 
     
     
         9 . The method of  claim 7 , wherein the cell-killing agent comprises an injectable selenite-containing hydrogel. 
     
     
         10 . The method of  claim 7 , wherein the cell-killing agent comprises an H2S donor, including at least one of sodium hydrosulfide, sodium sulfide, and GYY4137. 
     
     
         11 . A method for treating a tumor in a host in vivo, where the tumor has a centralized necrotic region, an intermediate hypoxic region, and a peripheral vascularized region, the method comprising the steps of:
 administering methylene blue to the tumor,   administering a super-physiological dose of vitamin C to the tumor, thereby producing leucomethylene blue and dehydroascorbic acid within the tumor,   administering a silver-containing antidotal agent to the host intravenously,   waiting for a period of time for the antidotal agent to perfuse into vascularized cells in the host, and   administering a cell-killing agent directly into the centralized region of the tumor, wherein the cell-killing agent comprises at least one of an injectable selenite-containing hydrogel, an H2S donor, including at least one of sodium hydrosulfide, sodium sulfide, and GYY4137,   whereby hydrostatic pressure within the tumor forces the cell-killing agent out of the centralized region of the tumor and through the intermediate region of the tumor in an interstitial flow, killing any non-vascularized cells in the centralized region and the intermediate region, and   whereby the cell-killing agent is neutralized by the antidotal agent as the cell-killing agent passes through the vascularized cells in the peripheral region.